Covis Pharma Sarl has acquired the U.S. rights to five pharmaceutical products from Sanofi-Aventis U.S. LLC.

The products, Nilandron, Plaquenil, Rilutek, Uroxatral and Kayexalate, had $114.6 million in sales for 2012. Sanofi will retain the rights to the assets outside of the U.S. Terms of the deal were not disclosed.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.